GenesWell 바카라 가상 머니 사이트 by Gencurix Demonstrates Enhanced Prognostic Stratification Compared to Oncotype DX

[by Ji, Yong Jun]Gencurix announced that its breast cancer prognostic test, GenesWell 바카라 가상 머니 사이트, has demonstrated enhanced prognostic stratification compared to Oncotype DX, the globally recognized 21-gene expression assay. The study underscores GenesWell 바카라 가상 머니 사이트’s ability to more effectively identify high-risk patients—particularly among premenopausal women and those with intermediate Oncotype DX scores, where treatment decisions often remain unclear.

The multicenter retrospective study evaluated 759 patients with early-stage HR+/HER2- breast cancer across five leading institutions in South Korea: Gangnam Severance Hospital, Samsung Medical Center, Asan Medical Center, the National Cancer Center, and Korea University Guro Hospital. This research builds upon previous work on 바카라 가상 머니 사이트 classification concordance in 2019 and follows up on comparative data presented at the 2023 ASCO Annual Meeting.

Published in Frontiers in Oncology, the study assessed recurrence-free survival (RFS) based on both the GenesWell 바카라 가상 머니 사이트 score and the Oncotype DX recurrence score.

Among all participants, GenesWell 바카라 가상 머니 사이트 reported a 7-year RFS of 95.0% for low-risk patients and 88.4% for high-risk patients—showing a greater absolute difference compared to Oncotype DX (93.7% vs. 88.1%). The hazard ratio (HR) between high- and low-risk groups for 바카라 가상 머니 사이트 was 2.469 (95% CI: 1.446–4.214), compared to 2.093 (95% CI: 1.138–3.850) for Oncotype DX, indicating the added value of GenesWell 바카라 가상 머니 사이트 in prognostic prediction.

In patients initially classified as low-risk (RS ≤25) by Oncotype DX, GenesWell 바카라 가상 머니 사이트 reclassified a subset as high-risk, with a statistically significant difference in RFS (HR = 2.477). These findings suggest that GenesWell 바카라 가상 머니 사이트 is capable of identifying patients at a high risk of recurrence who may not be detected by Oncotype DX alone.

The study also analyzed 209 women aged 50 or younger with intermediate Oncotype DX scores (RS 16–25). In this group, the 바카라 가상 머니 사이트 score revealed significant differences in recurrence risk, especially among those not treated with chemotherapy—highlighting the test’s utility in guiding adjuvant treatment decisions for premenopausal patients.

“This study, based on more than seven years of follow-up, shows that patients considered low-risk by Oncotype DX may still face substantial recurrence risk. GenesWell 바카라 가상 머니 사이트 provides meaningful additional prognostic information to support treatment decisions,” said Dr. Sung Gwe Ahn, lead author and breast surgeon at Gangnam Severance Hospital.

“These results offer valuable insights for tailoring chemotherapy recommendations—especially in younger women where 바카라 가상 머니 사이트 uncertainty often exists,” added Prof. Sae Byul Lee of Asan Medical Center, co-corresponding author.

GenesWell 바카라 가상 머니 사이트 is the only breast cancer prognostic test in Korea that has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) and is officially listed under the national health insurance code. It is also covered by private health insurance and is increasingly being adopted by top medical institutions across the country.

Notably, GenesWell 바카라 가상 머니 사이트 provides clinically meaningful prognostic insight even in populations where conventional genomic assays may be inconclusive—such as premenopausal patients. By delivering precise risk stratification, the test is becoming an important decision-making tool in everyday clinical practice.

“GenesWell 바카라 가상 머니 사이트 has shown strong prognostic performance in Korean patients. We’ve completed enrollment for a 600-patient post-market surveillance (PMS) study with a 10-year follow-up, further supporting confidence in its safety and clinical value,” said Dr. Sang Uk Woo of Korea University Guro Hospital.

Gencurix is actively expanding beyond Korea into international markets. GenesWell 바카라 가상 머니 사이트 is currently offered as a diagnostic service in several key Asian countries. Building on this momentum, Gencurix is pursuing strategic partnerships to extend its reach into China and Japan, with plans to seek insurance reimbursement and regulatory inclusion in the near future.